Lee Ainslie Pacira Bio Sciences, Inc. Transaction History

Maverick Capital LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$36.12 - $47.5 $210,326 - $276,592	5,823 New	5,823 $233,000
Q3 2021 Nov 15, 2021	SELL	$54.64 - $61.3 $60,541 - $67,920	-1,108 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$59.18 - $69.99 $65,571 - $77,548	1,108 New	1,108 $67,000
Q2 2020 Aug 14, 2020	SELL	$30.8 - $52.47 $1.48 Million - $2.53 Million	-48,159 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$28.4 - $50.7 $1.51 Million - $2.69 Million	-53,060 Reduced 52.42%	48,159 $1.62 Million
Q4 2019 Feb 14, 2020	SELL	$36.31 - $46.83 $2.58 Million - $3.33 Million	-71,161 Reduced 41.28%	101,219 $4.59 Million
Q3 2019 Nov 14, 2019	BUY	$35.66 - $44.99 $6.15 Million - $7.76 Million	172,380 New	172,380 $6.56 Million

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $870M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.